What it is
HGH 191AA is recombinant human growth hormone, also called somatropin.
Evidence boundary
HGH 191AA is an approved drug for defined endocrine indications.
Preparation and measurement
Reconstitution: 3.33 mg vial + 3 mL BAC = 1.11 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Week 1 | 200 mcg | 18.0 units (0.18 mL) | 5× weekly (Mon–Fri) | 1 mg/week |
| Week 2 | 300 mcg | 27.0 units (0.27 mL) | 5× weekly (Mon–Fri) | 1.5 mg/week |
| Week 3 | 400 mcg | 36.0 units (0.36 mL) | 5× weekly (Mon–Fri) | 2 mg/week |
| Week 4 | 500 mcg | 45.0 units (0.45 mL) | 5× weekly (Mon–Fri) | 2.5 mg/week |
| Week 5 | 600 mcg | 54.0 units (0.54 mL) | 5× weekly (Mon–Fri) | 3 mg/week |
| Week 6 | 700 mcg | 63.0 units (0.63 mL) | 5× weekly (Mon–Fri) | 3.5 mg/week |
| Week 7 | 800 mcg | 72.0 units (0.72 mL) | 5× weekly (Mon–Fri) | 4 mg/week |
| Week 8 (target) | 900 mcg | 81.0 units (0.81 mL) | 5× weekly (Mon–Fri) | 4.5 mg/week |
Week 1
- Dose
- 200 mcg
- Draw / measure
- 18.0 units (0.18 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 1 mg/week
Week 2
- Dose
- 300 mcg
- Draw / measure
- 27.0 units (0.27 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 1.5 mg/week
Week 3
- Dose
- 400 mcg
- Draw / measure
- 36.0 units (0.36 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 2 mg/week
Week 4
- Dose
- 500 mcg
- Draw / measure
- 45.0 units (0.45 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 2.5 mg/week
Week 5
- Dose
- 600 mcg
- Draw / measure
- 54.0 units (0.54 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 3 mg/week
Week 6
- Dose
- 700 mcg
- Draw / measure
- 63.0 units (0.63 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 3.5 mg/week
Week 7
- Dose
- 800 mcg
- Draw / measure
- 72.0 units (0.72 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 4 mg/week
Week 8 (target)
- Dose
- 900 mcg
- Draw / measure
- 81.0 units (0.81 mL)
- Frequency
- 5× weekly (Mon–Fri)
- Weekly total
- 4.5 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Light/anti-aging (200 mcg/day, 5 days/week): Conservative dose. Effects subtle but established. Lowest side-effect burden.
-
Standard (400 mcg/day, 5 days/week): Common research protocol. Balance of effect and tolerability.
-
Higher (600 mcg/day, 5 days/week): Body composition / performance research. Higher side effects: edema, joint pain, glucose intolerance.
-
Timing: Evening dosing (within 1 hour of bedtime) aligns with the natural overnight GH pulse during slow-wave sleep. Avoid eating for 1–2 hours after injection — elevated insulin blunts GH efficacy.
-
Cycle structure: 6–12 months continuous (with 5-on/2-off weekly pattern). Some protocols add 4-week breaks every 12 weeks.
-
Bloodwork cadence: IGF-1 and fasting glucose every 8–12 weeks to monitor for insulin resistance development.
-
IGF-1 response in approved indications
-
Edema
-
Joint pain
-
Carpal tunnel symptoms
-
Fasting glucose / insulin resistance
-
Headache or visual changes
-
Do not treat this like a gym protocol.
Practical rules
- Use only under endocrine care when indicated.
- Do not treat anti-aging internet schedules as a standard.
- Monitor glucose and IGF-1 as clinically appropriate.
- Keep the interpretation separate from unapproved bodybuilding advice.